UNSPSC 51183303: Sitagliptin

This classification denotes a protease inhibitor with the molecular formula C16H15F6N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) QFP0P1DV7Z, chemically known as 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate but more generally known as sitagliptin, which bears US NIH Compound Identifier 6451150.

UNSPSC 51183303 Sitagliptin is a Commodity code covering a specific pharmaceutical active ingredient, but the recent state and local opportunity tagged under it reflects broader pharmaceutical supply procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for multiple contracts supplying generic multi-source pharmaceuticals and over-the-counter products to participating state and local government facilities across Minnesota and Oregon. The procurement targets manufacturers able to supply products at volume through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—with detailed product specifications including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing location. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two of the three authorized wholesalers, and carry insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability. Pricing is evaluated at 75 percent weight, with additional scoring on fixed pricing structure (10 percent), compliance with data format requirements (5 percent), EDI capability (5 percent), and willingness to accept a 3 percent administrative fee (5 percent).

The RFP response deadline is March 26, 2026, with a question cutoff of February 18, 2026. Awarded vendors will be provided to wholesalers by May 15, 2026, with contracts effective July 1, 2026 for a two-year initial term with optional extensions; incumbent responders' amendments run through June 30, 2028. The solicitation does not disclose a specific budget or award value, and no set-aside designations are identified in the available documentation. Vendors are required to submit pricing and product information via the ePro procurement system in designated Excel format converted to CSV, with supporting documentation emailed to MMCAP_Infuse.RFP@state.mn.us. MMCAP reserves the right to award sole, dual, or multiple contracts based on therapeutic considerations, product availability, patient safety, and member-specific needs, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.